Early Detection of Prostate Cancer: AUA/SUO Guideline Part II: Considerations for a Prostate Biopsy
- PMID: 37096575
- PMCID: PMC11321723
- DOI: 10.1097/JU.0000000000003492
Early Detection of Prostate Cancer: AUA/SUO Guideline Part II: Considerations for a Prostate Biopsy
Abstract
Purpose: The summary presented herein covers recommendations on the early detection of prostate cancer and provides a framework to facilitate clinical decision-making in the implementation of prostate cancer screening, biopsy, and follow-up. This is Part II of a two-part series focusing on initial and repeat biopsies, and biopsy technique. Please refer to Part I for discussion of initial prostate cancer screening recommendations.
Materials and methods: The systematic review utilized to inform this guideline was conducted by an independent methodological consultant. The systematic review was based on searches in Ovid MEDLINE and Embase and Cochrane Database of Systematic Reviews (January 1, 2000-November 21, 2022). Searches were supplemented by reviewing reference lists of relevant articles.
Results: The Early Detection of Prostate Cancer Panel developed evidence- and consensus-based guideline statements to provide guidance in prostate cancer screening, initial and repeat biopsies, and biopsy technique.
Conclusions: The evaluation of prostate cancer risk should be focused on the detection of clinically significant prostate cancer (Grade Group 2 or higher [GG2+]). The use of laboratory biomarkers, prostate MRI, and biopsy techniques described herein may improve detection and safety when a prostate biopsy is deemed necessary following prostate cancer screening.
Keywords: AIP; ASAP; HGPIN; MRI; PI-RADS; PSA; biomarkers; biopsy technique; early detection of prostate cancer; imaging; prostate cancer biopsy; prostate cancer screening; transperineal; transrectal.
Figures
Similar articles
-
Early Detection of Prostate Cancer: AUA/SUO Guideline Part I: Prostate Cancer Screening.J Urol. 2023 Jul;210(1):46-53. doi: 10.1097/JU.0000000000003491. Epub 2023 Apr 25. J Urol. 2023. PMID: 37096582 Free PMC article.
-
Salvage Therapy for Prostate Cancer: AUA/ASTRO/SUO Guideline Part I: Introduction and Treatment Decision-Making at the Time of Suspected Biochemical Recurrence after Radical Prostatectomy.J Urol. 2024 Apr;211(4):509-517. doi: 10.1097/JU.0000000000003892. Epub 2024 Feb 29. J Urol. 2024. PMID: 38421253
-
Salvage Therapy for Prostate Cancer: AUA/ASTRO/SUO Guideline Part II: Treatment Delivery for Non-metastatic Biochemical Recurrence After Primary Radical Prostatectomy.J Urol. 2024 Apr;211(4):518-525. doi: 10.1097/JU.0000000000003891. Epub 2024 Feb 29. J Urol. 2024. PMID: 38421243
-
Prostate Magnetic Resonance Imaging, with or Without Magnetic Resonance Imaging-targeted Biopsy, and Systematic Biopsy for Detecting Prostate Cancer: A Cochrane Systematic Review and Meta-analysis.Eur Urol. 2020 Jan;77(1):78-94. doi: 10.1016/j.eururo.2019.06.023. Epub 2019 Jul 18. Eur Urol. 2020. PMID: 31326219
-
Is magnetic resonance imaging-targeted biopsy a useful addition to systematic confirmatory biopsy in men on active surveillance for low-risk prostate cancer? A systematic review and meta-analysis.BJU Int. 2018 Dec;122(6):946-958. doi: 10.1111/bju.14358. Epub 2018 Jun 6. BJU Int. 2018. PMID: 29679430
Cited by
-
Efficacy of fosfomycin compared to second generation cephalosporin flumarin as antimicrobial prophylaxis for transrectal ultrasound-guided prostate biopsy: a single center retrospective study.BMC Urol. 2023 Dec 19;23(1):211. doi: 10.1186/s12894-023-01391-7. BMC Urol. 2023. PMID: 38114968 Free PMC article.
-
Role of region-of-interest magnetic resonance imaging fusion biopsy in mitigating overtreatment of localized prostate cancer - A retrospective cohort study.Eur J Radiol Open. 2025 Mar 7;14:100642. doi: 10.1016/j.ejro.2025.100642. eCollection 2025 Jun. Eur J Radiol Open. 2025. PMID: 40125074 Free PMC article.
-
Transcriptomic miRNA and mRNA signatures in primary prostate cancer that are associated with lymph-node invasion.Clin Transl Med. 2025 Apr;15(4):e70288. doi: 10.1002/ctm2.70288. Clin Transl Med. 2025. PMID: 40219635 Free PMC article.
-
Comparing Two Targeted Biopsy Schemes for Detecting Clinically Significant Prostate Cancer in Magnetic Resonance Index Lesions: Two- to Four-Core versus Saturated Transperineal Targeted Biopsy.Cancers (Basel). 2024 Jun 23;16(13):2306. doi: 10.3390/cancers16132306. Cancers (Basel). 2024. PMID: 39001369 Free PMC article.
-
Residents and Consultants Have Equal Outcomes When Performing Transrectal Fusion Biopsies: A Randomized Clinical Trial.Curr Oncol. 2024 Jan 29;31(2):747-758. doi: 10.3390/curroncol31020055. Curr Oncol. 2024. PMID: 38392049 Free PMC article. Clinical Trial.
References
-
- Eastham JA, Boorjian SA and Kirkby E: Clinically localized prostate cancer: Aua/astro guideline. J Urol 2022; 208: 505. - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous